Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, posted on LinkedIn:
”Great result
I was really pleased to hear from Brian O’Mahony that the World Health Organisation (WHO) has listened and changed its lists of core and complementary products to treat diseases when it comes to haemophilia. Their previous, (still the current), list suggests cryoprecipitate as a core treatment for haemophilia, which is strange as it has poor efficacy and is not safe in the countries likely to use it. Congratulations to the World Federation of Hemophilia for all their hard work representing the haemophilia community and persuading the WHO to implement this change.
The new recommendations appearing on the next edition of the lists will now show:
a) Removal of pathogen-reduced cryoprecipitate and cryoprecipitate from the core list
b) Plasma-derived FVIII and FIX will be moved from the complimentary to the core list
c) Prothrombin complex concentrate (PCC) for the treatment of haemophilia B will be removed from the list due to the thrombotic risk
d) Recombinant FVIII and FIX will now be on the core list for prophylaxis and on-demand treatment
e) Emicizumab will be added to the complimentary list for prophylaxis in haemophilia A for persons with and without inhibitors.
Two key lessons:
1. When the haemophilia community works together, it achieves results
2. The WHO should rely on experts who are directly involved in the treatment of a specific disease.”
Stay updated with Hemostasis Today.
-
Oct 24, 2025, 11:46Rocío Vacik Díaz on Impact of LVAD Implantation at ECTH 2025
-
Oct 23, 2025, 06:03Melanie Daniel: Wonderful Presentation on Emicizumab by Mickael Rosa at ECTH
-
Oct 22, 2025, 06:17We Will Continue to Raise Awareness and Remind Rveryone That Donating Blood Means Saving Lives - Yeolyan Hematology and Oncology Center
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 24, 2025, 12:08Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
-
Oct 24, 2025, 12:03Melissa Glasner on Integration of Gene Therapy Into Hemophilia Care
-
Oct 24, 2025, 11:41Yaping Zhang on Platelet Adhesion Receptors
-
Oct 24, 2025, 11:37Omid Jafari and Colleagues Present the VTE-BERT Natural Language Processing Model
-
Oct 24, 2025, 11:34Insights on IV Thrombolysis and Mechanical Thrombectomy from Benjamin Maier and Colleagues
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 24, 2025, 11:28Louise Bannon and Thomas Reiser Thank World Thrombosis Day Supporters Around The World
-
Oct 24, 2025, 10:48Melanie Daniel Congratulates Mickael Rosa and Antoine Rauch on Winning Bernd R. Binder Prize
-
Oct 24, 2025, 10:47Nan van Geloven Was Awarded The Prestigious Vidi Grant
-
Oct 23, 2025, 06:52Louise Bannon: Thrilled to Witness The Incredible Reach of This Year's World Thrombosis Day!
-
Oct 23, 2025, 06:50Caitlin Raymond to Speak at The 11th Annual Bloodless Medicine and Surgery Society Conference